Advertisement

Murine Models of Bone Sarcomas

  • Camille Jacques
  • Nathalie Renema
  • Benjamin Ory
  • Carl R. Walkley
  • Agamemnon E. Grigoriadis
  • Dominique HeymannEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1914)

Abstract

This chapter describes the procedures for inducing bone sarcoma in mice. Two models based on inoculation of cancer cells in paraosseous and intraosseous site will be described. In addition to providing technical aspects of anesthesia and surgical options, key information of cell preparation and postoperative follow-up will be discussed.

Key words

Bone sarcoma Osteosarcoma Ewing sarcoma Chondrosarcoma Cell-injection Murine preclinical models Genetically-engineered mouse models 

References

  1. 1.
    Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F (2010) Zoledronic acid as a new adjuvant therapeutic strategy for Ewing’s sarcoma patients. Cancer Res 70:7610–7619CrossRefGoogle Scholar
  2. 2.
    Cherrier B, Gouin F, Heymann MF, Thiéry JP, Rédini F, Heymann D, Duteille F (2005) A new experimental rat model of osteosarcoma established by intrafemoral tumor cell inoculation, useful for biology and therapy investigations. Tumour Biol 26:121–130CrossRefGoogle Scholar
  3. 3.
    Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, Hong SH, Çelik H, Tirode F, Tuckermann J, Toretsky JA, Kenner L, Kovar H, Lee S, Sweet-Cordero EA, Nakamura T, Moriggl R, Delattre O, Üren A (2017) Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget 8:34141–34163CrossRefGoogle Scholar
  4. 4.
    Guijarro MV, Ghivizzani SC, Gibbs CP (2014) Animal models in Osteosarcoma. Front Oncol 4:189CrossRefGoogle Scholar
  5. 5.
    Sampson VB, Kamata DF, Kolh EA (2013) Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery. Expert Opin Drug Discov 8:1181–1189CrossRefGoogle Scholar
  6. 6.
    Ng AJM, Mutsaers AJ, Wlakley CR (2012) Genetically engineered mouse models and human osteosarcoma. Clinical Sarcoma Res 2:19CrossRefGoogle Scholar
  7. 7.
    Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E (2015) The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget 6:18875–18890CrossRefGoogle Scholar
  8. 8.
    Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlström Å, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA (2014) Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep 9:829–841CrossRefGoogle Scholar
  9. 9.
    Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, Dyer MA (2016) The childhood solid tumor network: a new resource for the developmental biology and oncology research communities. Dev Biol 411:287–293CrossRefGoogle Scholar
  10. 10.
    Murakami T, Igarashi K, Kawaguchi K, Kiyuna T, Zhang Y, Zhao M, Hiroshima Y, Nelson SD, Dry SM, Li Y, Yanagawa J, Russell T, Federman N, Singh A, Elliott I, Matsuyama R, Chishima T, Tanaka K, Endo I, Eilber FC, Hoffman RM (2017) Tumour-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. Oncotarget 8:8035–8042PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Camille Jacques
    • 5
  • Nathalie Renema
    • 1
  • Benjamin Ory
    • 5
  • Carl R. Walkley
    • 2
  • Agamemnon E. Grigoriadis
    • 3
  • Dominique Heymann
    • 4
    Email author
  1. 1.INSERM, U1238, University of NantesNantesFrance
  2. 2.Department of Medicine, St. Vincent’s Institute of Medical ResearchSt. Vincent’s Hospital, University of MelbourneMelbourneAustralia
  3. 3.Centre for Craniofacial and Regenerative BiologyKing’s College London Guy’s HospitalLondonUK
  4. 4.Institut de Cancérologie de l’Ouest, INSERM, UMR1232, Université de Nantes, Université d’Angers, Tumour Heterogeneity and Precision MedicineNantesFrance
  5. 5.INSERM, UMR1238, Bone Sarcoma and Remodeling of Calcified Tissues, Université de Nantes, Nantes Atlantique UniversitésNantesFrance

Personalised recommendations